文献速递关节外科

全膝关节置换术前治疗丙型肝炎具有成本效益:一项马尔可夫分析

Treating Hepatitis C Before Total Knee Arthroplasty is Cost-Effective: A Markov Analysis.
PubMed 文献 · J Arthroplasty · 2023-08-19

本研究采用马尔可夫模型,基于已发表文献数据,比较全膝关节置换术前不治疗与使用直接抗病毒药物(DAA)治疗丙型肝炎病毒(HCV)的成本效益。结果显示,DAA治疗增加13.5个质量调整生命年(QALY),成本为114,900美元,增量成本效益比(ICER)为16,800美元/QALY,低于100,000美元/QALY的支付意愿阈值。作者认为术前DAA治疗可降低假体周围关节感染风险且具有成本效益,应强烈考虑在择期全膝关节置换术前治疗HCV患者。

要点

  • HCV患者全膝关节置换术前使用DAA的ICER为16,800美元/QALY,低于100,000美元/QALY阈值。
  • 不治疗与DAA治疗分别增加8.1和13.5个QALY,成本分别为25,000和114,900美元。
  • 敏感性分析显示ICER受患者年龄、通货膨胀率、DAA成本与疗效、HCV相关死亡率及DAA降低假体周围关节感染率的影响。

核心结论

  • 全膝关节置换术前使用直接抗病毒药物治疗可降低假体周围关节感染风险且具有成本效益。
  • 应强烈考虑在择期全膝关节置换术前治疗丙型肝炎病毒患者。

研究设计与样本

  • 马尔可夫模型,输入值来自已发表文献,评估全膝关节置换术前DAA治疗的成本效益。
  • 输入值包括事件概率、死亡率、成本以及有和无HCV患者的健康状态质量调整生命年值。
  • 有HCV患者被建模为假体周围关节感染率增加(9.9%至0.7%)。
  • 比较不治疗与DAA的增量成本效益比与100,000美元/QALY的支付意愿阈值。
  • 进行敏感性分析以探究输入变量不确定性的影响。

主要发现

  • 不治疗情况下全膝关节置换增加8.1个QALY,成本为25,000美元。
  • DAA治疗增加13.5个QALY,成本为114,900美元。
  • DAA与不治疗相比的ICER为16,800美元/QALY,低于100,000美元/QALY的支付意愿阈值。
  • 敏感性分析表明ICER受患者年龄、通货膨胀率、DAA成本和有效性、HCV相关死亡率以及DAA诱导的假体周围关节感染率降低的影响。

关键数值与推荐

  • 支付意愿阈值为100,000美元/QALY。
  • 有HCV患者假体周围关节感染率建模为9.9%至0.7%。

临床怎么用

  • 作者认为应强烈考虑在择期全膝关节置换术前治疗丙型肝炎病毒患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients who have the hepatitis C virus (HCV) have increased mortality and complication rates following total knee arthroplasty (TKA). Recent advances in HCV therapy have enabled clinicians to eradicate the disease using direct-acting antivirals (DAAs); however, its cost-effectiveness before TKA remains to be demonstrated. The aim of this study was to perform a cost-effectiveness analysis comparing no therapy to DAAs before TKA. METHODS: A Markov model using input values from the published literature was performed to evaluate the cost-effectiveness of DAA treatment before TKA. Input values included event probabilities, mortality, cost, and health state quality-adjusted life-year (QALY) values for patients who have and do not have HCV. Patients who have HCV were modeled to have an increased rate of periprosthetic joint infection (PJI) infection (9.9 to 0.7%). The incremental cost-effectiveness ratio (ICER) of no therapy versus DAA was compared to a willingness-to-pay threshold of $100,000/QALY. Sensitivity analyses were performed to investigate the effects of uncertainty associated with input variables. RESULTS: Total knee arthroplasty in the setting of no therapy and DAA added 8.1 and 13.5 QALYs at a cost of $25,000 and $114,900. The ICER associated with DAA in comparison to no therapy was $16,800/QALY, below the willingness-to-pay threshold of $100,000/QALY. Sensitivity analyses demonstrated that the ICER was affected by patient age, inflation rate, DAA cost and effectiveness, HCV-associated mortality, and DAA-induced reduction in PJI rate. CONCLUSION: Direct-acting antiviral treatment before TKA reduces risk of PJI and is cost-effective. Strong consideration should be given to treating patients who have HCV before elective TKA. LEVEL OF EVIDENCE: Cost-effectiveness Analysis; Level III.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Kalyanasundaram G, Feng JE, Congiusta F, et al. Treating Hepatitis C Before Total Knee Arthroplasty is Cost-Effective: A Markov Analysis. J Arthroplasty. 2023. PMID: 37604270. doi:10.1016/j.arth.2023.08.053

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。